Shares of TherapeuticsMD (NASDAQ: TXMD) jumped 34% in August, according to data provided by S&P Global Market Intelligence, after the drugmaker reported solid second-quarter earnings and increased its guidance for the year.
Part of the August jump had to do with the disappointing first quarter that TherapeuticsMD posted. Shares were priced for more of the same.
Instead, sales of Imvexxy, the company's estradiol inserts for menopause-related dyspareunia, bounced back, with prescriptions up 41% quarter over quarter. More importantly, July was even stronger with about 45,500 prescriptions dispensed and paid for by patients, compared to approximately 106,000 prescriptions in all of the second quarter.